Chromocell Therapeutics Corp (CHRO)
NYSEAMERICAN: CHRO · IEX Real-Time Price · USD
1.640
-0.350 (-17.59%)
At close: Apr 18, 2024, 3:55 PM
1.320
-0.320 (-19.51%)
After-hours: Apr 18, 2024, 5:15 PM EDT
Chromocell Therapeutics Statistics
Total Valuation
CHRO has a market cap or net worth of $7.20 million. The enterprise value is $10.75 million.
Market Cap | 7.20M |
Enterprise Value | 10.75M |
Important Dates
The next estimated earnings date is Monday, May 20, 2024, before market open.
Earnings Date | May 20, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
CHRO has 5.88 million shares outstanding. The number of shares has increased by 193.25% in one year.
Shares Outstanding | 5.88M |
Shares Change (YoY) | +193.25% |
Shares Change (QoQ) | +29.66% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | n/a |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.02
Current Ratio | 0.02 |
Quick Ratio | n/a |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -13.23 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -11,824.50% |
Return on Capital (ROIC) | n/a |
Revenue Per Employee | n/a |
Profits Per Employee | -$2.46M |
Employee Count | 3 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (1Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | n/a |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 31.01 |
Average Volume (30 Days) | 33,645 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -6.86M |
Pretax Income | -7.38M |
Net Income | -7.38M |
EBITDA | -6.86M |
EBIT | -6.86M |
Earnings Per Share (EPS) | -$5.78 |
Balance Sheet
The company has $96,391 in cash and $1.27 million in debt, giving a net cash position of -$1.17 million or -$0.20 per share.
Cash & Cash Equivalents | 96,391 |
Total Debt | 1.27M |
Net Cash | -1.17M |
Net Cash Per Share | -$0.20 |
Equity / Book Value | -6.44M |
Book Value Per Share | -1.10 |
Working Capital | -6.44M |
Cash Flow
Operating Cash Flow | -981,031 |
Capital Expenditures | n/a |
Free Cash Flow | -981,031 |
FCF Per Share | -$0.77 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
CHRO does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -193.25% |
Shareholder Yield | -193.25% |
Earnings Yield | -77.04% |
FCF Yield | -10.24% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |